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Running title: MASPs in the lectin pathway and beyond 
 
 
 
Summary: Mannose-binding-lectin (MBL)-associated serine proteases (MASPs) are the enzymatic 
constituents of the lectin pathway of the complement system. They are complexed with large 
pattern recognition molecules (PRMs) such as MBL, other collectins, and ficolins. The main 
function of two out of the three MASPs has crystallized lately: MASP-1 autoactivates first, then it 
activates MASP-2, and finally both participate in the formation of the C4b2a convertase. In 
addition to this both enzymes are involved in several other processes, which are subject to intense 
research nowadays. Notably MASP-1, as a promiscuous enzyme, has been implicated in the 
coagulation cascade, in the kinin-generating contact system, and in cellular activation through 
protease-activated receptor (PAR) cleavage on endothelial cells. The third protease MASP-3 has 
emerged recently as the protease responsible for pro-factor D activation in resting blood, 
providing a fundamental link between two complement pathways. At present all three MASPs 
have at least one well-defined role and several other possible functions were implicated. Defect or 
more likely over-activation of MASPs may culminate into diseases such as ischemia-reperfusion 
injury (IRI) hence MASPs are all potential targets of drug development. 
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Introduction and brief history 
 
When Ikeda and colleagues showed in 1987 that a blood-borne lectin isolated from rat 
serum (MBP which is now called MBL) is capable of hemolysing sheep erythrocytes coated with 
yeast mannan (1), a new era of research began that changed our view about the complement 
system for ever. First, it was assumed that MBL (mannose-binding lectin, aka mannan-binding 
lectin, or mannan-binding protein) only supplements the well known classical pathway, since it can 
bind and activate the tetramer consisting of two C1r and two C1s proteases (2). Later, it became 
gradually evident that a new, independent activation pathway of the complement cascade had 
been discovered. The scientific impact of this discovery can be compared only to the discovery of 
the alternative (properdin) pathway by Pillemer in the early 1950s (3). The lectin pathway, the 
youngest according to the chronology of discovery, represents a very ancient type of innate 
immune defense. As an ancient pathway, the lectin pathway is intimately connected to the 
classical and the alternative pathways. In this review we will delineate the mechanism of lectin 
pathway activation, the cross-talk between the lectin pathway and the other complement 
pathways and we will also give account of the role of the lectin pathway enzymes in the innate 
immune defense outside the complement system. 
Genome encoded pattern recognitions molecules (“receptors”) are present everywhere in 
the body: inside the cells, on the cell surface and in the extracellular space. In the bloodstream, 
pattern recognition molecules circulate to monitor the presence of invading pathogens and 
dangerous self-structures (e.g. dead cells, cancer cells). C1q, the pattern recognition molecule of 
the classical pathway binds mainly to immune complexes, bridging the innate and adaptive 
immune responses. MBL and the other pattern recognition molecules of the lectin pathway 
recognize the dangerous structures immediately as they appear in the bloodstream long before 
the development of the adaptive immune response. The lectin pathway therefore represents the 
very first line of defense against infection. Since the discovery of the MBL the inventory of the 
pattern recognition molecules has been continuously increasing (4). MBL, ficolin-1,-2,-3, collectin-
10 (CL-L1), collectin-11 (CL-K1) are the known molecules that can initiate lectin pathway activation. 
After the pattern recognition molecules bind to the dangerous particles an enzymatic signal is 
generated by associated serine proteases. These serine proteases are present as zymogens in the 
circulating initiation complexes and become activated upon the pattern recognition molecules 
bind to their targets. The first enzymatic step is usually an autoactivation. The initial proteolytic 
signal is then further amplified by a proteolytic cascade. There are three MBL-associated serine 
proteases (MASPs), MASP-1, -2 and -3. Since MASP-1 is the most abundant one (having ~140 nM 
serum concentration), it was discovered first and it was believed that it is a C1s-like protease, as 
the MASP-1 preparation cleaved C4 and C2 generating the classical/lectin pathway C3 convertase 
complex (C4b2a) (5). Later it turned out that the C1s-like protease responsible solely for C4 and 
partially for C2 cleavage was in fact a minor “contaminating” component co-purified originally 
with MASP-1, it was the later discovered MASP-2 (having 6 nM serum concentration) (6). MASP-1 
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can autoactivate and cleave C2 but not C4, therefore cannot generate C3 convertase (7). It was 
also shown that MASP-2 can autoactivate in vitro and an initiation complex consisting of MBL and 
MASP-2 molecules can initiate lectin pathway activation without the contribution of any other 
proteases (8). This view about the superiority of MASP-2 persisted for more than a decade while 
the physiological role of MASP-1 was a subject of intense debate among complementologists. In 
the meantime in 2001, quite unexpectedly, a third MBL-associated protease (MASP-3) was 
discovered (9). The physiological role of this protease was even more mysterious than that of 
MASP-1: in spite that MASP-3 binds to the pattern recognition molecules, it cannot cleave any 
components of the C3/C5 convertase complexes. Consequently, when adding MASP-3 to the MBL-
MASPs complexes it acts as an inhibitor of lectin pathway activation as it displaces MASP-2 and 
MASP-1. Moreover, C1 inhibitor, the natural serpin type inhibitor of C1r, C1s, MASP-1 and MASP-2 
does not inhibit the activity of MASP-3 on synthetic substrates (10). Besides the three serine 
proteases, two non-catalytic proteins can also be found in the initiation complexes. MAp19 (alias 
MAP-2 or sMAP) consists of the two N-terminal domains (CUB1 and EGF) of MASP-2 (11). MAp44 
(alias MAP-1) represents the four N-terminal domains of MASP-1 (CUB1, EGF, CUB2 and CCP1) 
(12). Now we have two genes and five gene products due to alternative spicing (Fig. 1). MASP-1, 
MASP-3 and MAp44 are the alternative splice products of the MASP1 gene, whereas MASP-2 and 
MAp19 are that of the MASP2 gene. 
The picture of lectin pathway activation is quite complicated since we have at least six 
pattern recognition molecules, three associated serine proteases and two associated proteins. The 
composition and the stoichiometry of the initiation complexes are not well characterized and 
there are many open questions regarding the role of the individual components in the complex 
mechanism of the initiation of the innate immune response. The significance of the research of 
lectin pathway is underlined by the fact that uncontrolled activation of this pathway contributes to 
the development and worsening of serious disease conditions (e.g. myocardial infarction, stroke) 
in which the proteolytic activity of MASPs plays a major role (13). During the recent years there 
has been an intense progress in the characterization of enzymatic and structural properties as well 
as the physiological roles of the MBL-associated serine proteases. In the following chapters we will 
provide an up-to-date picture about the actions of MASPs in the complement system and beyond. 
 
 
The individual roles of MASPs in lectin pathway activation 
 
General approaches to study protein networks 
 
Like most biological processes, the activation of the lectin pathway is also governed by 
specific protein-protein interactions and some of these interactions also involve highly specific 
proteolytic steps. With other words, the lectin pathway is a protein network and also a proteolytic 
cascade. There are three major approaches to study the mechanism of action of protein networks. 
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Nowadays a quite widely used approach is to genetically remove individual components 
from the in vivo system either by gene knockout (KO) or gene silencing (gene knockdown) 
experiments. Such powerful experiments can often quickly identify major functions of the 
individual proteins. However, several important aspects of KO experiments should be carefully 
considered when interpreting the results. When KO animals or genetically deficient humans are 
studied one should be aware that the corresponding protein has been missing throughout the 
entire embryogenesis and in fact the entire lifetime of the individual. This might generate complex 
indirect effects including compensatory biological processes. In addition, in a network, individual 
components might have multiple interacting surfaces for multiple network components. Removal 
of such central components can disrupt many interactions simultaneously and the observed 
results can be again very complex. 
When applying the classic biochemical approach, which is also the most tedious one, each 
member is isolated from its natural source or produced as recombinant protein. Then, each 
protein is individually characterized in vitro both functionally (binding characteristics, stability, 
enzymatic properties etc.) and structurally (X-ray crystallography and / or NMR). Then, the well 
characterized purified compounds are combined and further analyzed in various complexes to 
ultimately reconstruct the original network. If all components have indeed been identified, ideally, 
the reconstructed network should recapitulate the functional properties of the natural one. 
The third approach is to keep the original network as close to the natural state as possible 
and disrupt individual protein interaction sites questioning the function of a single protein-protein 
interaction or a single enzyme activity. To do so, one needs to have a natural or manmade 
compound that selectively binds to the given binding site with sufficiently high affinity. We 
decided to decipher individual roles of each MASP enzyme in lectin pathway activation by 
combining the latter two approaches. 
 
Development of specific MASP-1 and MASP-2 inhibitors 
 
As an important first step we established a robust bacterial expression system to produce 
the catalytic fragments of the MASP enzymes in large quantities and high quality. These fragments 
do not dimerize or bind to pattern recognition molecules, but carry all the enzymatic properties of 
the entire protease. Zymogens of all three MASP enzymes were expressed in E. coli leading to non-
toxic inclusion bodies and the proteins were taken through a refolding procedure to generate 
correctly folded native forms (7). 
Even this isolation procedure was quite informative. Whatever we tried, zymogen MASP-1 
went through autoactivation at early phase of the isolation process suggesting high autoactivation 
potency. On the other hand, zymogen MASP-2 became activated only during a later 
chromatographic step which caused high local concentration of the proenzyme. We were able to 
prevent the process by keeping the concentration low and performing the purification at low 
temperature (14). Zymogen MASP-3 on the other hand did not autoactivate at all. 
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It was shown by Vorup-Jensen et al (8) that at low concentration, or when complexed with 
MBL in solution, proenzyme MASP-2 remained in zymogen form. On the other hand, when the 
MBL-zymogen MASP-2 complex was transferred onto mannan-coated surface, MASP-2 
autoactivation occurred. Nevertheless, the authors also noted that the rate of MASP-2 activation 
was considerably lower than observed in natural MBL-MASP complexes generated by incubating 
MBL with MBL-deficient serum. These latter complexes have a more diverse composition 
containing not only MASP-2, but also MASP-1 and other MBL associated components. 
It has been gradually established by the contribution of several research groups that MASP-
3 cannot cleave either C2 or C4; MASP-1 is unable to cleave C4 but cleaves C2; and among the 
MASPs only MASP-2 can cleave both C2 and C4 generating a C4b2a type C3 convertase (6, 7, 9, 15-
18). 
This knowledge combined with the observed characteristic autocatalytic properties of the 
three MASP enzymes led to a perception and an activation model that dominated the field for 
over a decade. Namely, MASP-2 was considered as the single key initiator of the lectin pathway 
activation as it can autoactivate and generate a C3 convertase by its own. MASP-1 was considered 
to be at most an auxiliary enzyme that provides some of the activated C2 component for the 
convertase (19), although it was also shown in a murine model that MASP-1 facilitates MASP-2 
activation through an unknown mechanism (20). MASP-3 was believed to be a negative pathway 
regulator. 
This was the state of knowledge when we decided to develop MASP-1 and MASP-2 
inhibitors for two different purposes. Accepting the view that MASP-2 is the single key enzyme we 
aimed to develop a specific MASP-2 inhibitor to selectively block the lectin pathway while leaving 
the other two pathways fully functional. This was important as such inhibitors have been unknown 
from nature. The major negative regulator of the lectin pathway, the C1 inhibitor serpin is also a 
potent inhibitor of the classical complement pathway enzymes. We also aimed to develop a 
specific inhibitor against MASP-1 in order to quantitatively assess its contribution to the lectin 
pathway. 
By that time we had already solved the X-ray structures of both the zymogen and the active 
form of MASP-2 and also the active form of MASP-1 (21, 14, 22). Based on the active enzyme 
structures it was clear that compared to the archetype proteinase trypsin, the substrate binding 
cleft of MASP-1 is in some degree while that of MASP-2 is largely blocked by large surface loops. 
This suggested that our novel inhibitor should be as small as possible in order to minimize the 
degree of clash with the large enzyme loops. 
But how can one develop a selective binder against a particular protein site? To our 
knowledge in silico methods are not powerful enough yet, and the only experimental approaches 
are either selection of the binders from a library of synthetic small molecules or developing a 
protein binder through directed evolution. 
Small molecules (below 500 Dalton) can be very useful but are usually limited to cases 
when the target has a well-defined deep binding pocket and that pocket is unique to the target 
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protein i.e. there are no other related proteins with identical or highly similar binding sites. This is 
clearly not the case with the MASP enzymes. These enzymes are all trypsin-like enzymes having a 
deep S1 pocket (23) with a negatively charges Asp at its bottom. The plasma contains dozens of 
evolutionary related trypsin-like serine proteinases, e.g. the members of the blood coagulation 
cascade, the three complement activation pathways and the complement convertases, and also 
plasminogen activator, plasmin, kallikreins etc. There are many known small molecule serine 
proteinase inhibitors, but almost all of them are quite nonspecific inhibiting multiple trypsin-like 
enzymes with similar efficiency.  
So, we decided to develop MASP-1 and MASP-2 inhibitors by evolving them from an 
existing natural substrate-like reversible trypsin inhibitor. To minimize the clash with the substrate 
binding cleft covering enzyme loops our first choice was the 14 residue Sunflower Trypsin Inhibitor 
(SFTI), which is the smallest natural serine proteinase inhibiting peptide. Nevertheless, it is still 
much larger than a typical small molecule promising considerable specificity.  
We prepared a library by randomizing six presumed proteinase contacting positions of SFTI 
through combinatorial mutagenesis. The SFTI-library was displayed on the surface of M13 phage in 
a monovalent fashion and selected for binding separately on MASP-1 and MASP-2 (24). After the 
phage display selection procedure we chose two clones that as a set provided the best research 
tools. One of these, SFMI-2 inhibited MASP-2 with 180 nM equilibrium inhibition constant (KI) 
while did not inhibit MASP-1 at all, while the other one, SFMI-1 had a 65 nM KI on MASP-1 but also 
inhibited MASP-2 with a micromolar KI value.  
In the WIESLAB Complement system Screen assay (25), which measures the activation of 
the three complement pathways separately, SFMI-2 proved to be a selective lectin pathway 
inhibitor, the very first of its kind, with a 9.9 µM IC50 value. The observed complete pathway 
inhibition was in perfect accordance with the generally accepted central role of MASP-2. SFMI-1 
turned to be also a selective lectin pathway inhibitor having a 3.2 µM IC50 value. Based on the 
prevailing activation model of the lectin pathway the potency of this inhibitor was unexpectedly 
high. Compared to SFMI-2 SFMI-1 is a 6-fold weaker MASP-2 inhibitor, but it is actually a 3-fold 
more efficient lectin pathway blocker, which altogether represents a 20-fold discrepancy. 
To dissect the potential source of this discrepancy we conducted a C3 and a C4 deposition 
assay, both designed such that the inhibitor was added to non-activated serum containing the 
PRM-associated MASPs in proenzyme form and then the mixture was transferred to mannan-
coated activating surface. Both assays recapitulated the WIESLAB assay results: SFMI-1, which 
inhibits both MASP-1 and MASP-2 was 15-20-fold more potent than SFMI-2. We also performed a 
different type of C4-deposition assay, in which we first activated the MBL-bound MASPs on 
mannan-coated wells and then added purified C4 mixed with either SFMI-1 or SFMI-2 and 
measured C4b deposition (26). In these assays the ratios of IC50 values of the two inhibitors did not 
track with those in the WIESLAB assay and the previous C3 and C4 deposition assays, but these 
ratios were in good accordance with the KI values of SFMI-1 and SFMI-2 measured on MASP-2. We 
concluded that once MASP-2 is already activated, the MASP-1 inhibiting capacity of SFMI-1 has no 
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relevance and only its MASP-2 inhibiting capacity matters. On the other hand, when we started 
with proenzyme MASPs, inhibiting MASP-1 had a major contribution to the suppression of MASP-2 
function. Altogether the results proved that MASP-1 contributes to MASP-2 activation, but the 
quantitative proportion of this contribution could not have been determined without a MASP-1 
selective inhibitor. 
In order to solve this problem we decided to evolve a second generation of MASP inhibitors 
starting with a member of a different substrate-like inhibitor, namely the Pacifastin family. We did 
so, because our results with the SFMI inhibitors suggested that their small size, which we assumed 
to be important for avoiding steric clash, might actually limit their selectivity. The Pacifastin 
inhibitor SGPI-2 that we chose is a 3-disulfide stabilized 35 amino acid residues small protein that 
provides a larger interacting site for the enzymes. After phage display selection of an SGPI library 
we tested the inhibitory characteristics of several variants produced as recombinant proteins. We 
decided to use two variants for further studies. One of them, SGMI-1 is a 7 nanomolar inhibitor of 
MASP-1 and a 58 micromolar inhibitor of MASP-2, while the other one, SGMI-2 is a 6 nanomolar 
inhibitor of MASP-2 and it does not inhibit MASP-1 at all (27). With this monospecific pair of 
inhibitors we could finally analyze the selective contribution of MASP-1 to the activation of MASP-
2 and the lectin pathway in general. 
SGMI-2, as expected was found to be a potent lectin pathway inhibitor. Compared to SFMI-
2 SGMI-2 binds 30-fold tighter to MASP-2 (6 nM versus 180 nM KI value on MASP-2) and based on 
the IC50 values of the WIESLAB assays SGMI-2 is 150-times more potent lectin pathway blocker 
than SFMI-2 (66 nM versus 9.9 µM value). Importantly, SGMI-2 is also pathway selective as it does 
not inhibit the classical or the alternative pathways and it is ineffective on the C3 and C5-
convertases as well. 
 
MASP-1 is the exclusive activator of MASP-2 
 
When testing SGMI-1 in serum-based lectin pathway activation assays we expected partial 
inhibition in accordance with the presumed contributing role of MASP-1 to MASP-2 activation. In 
contrast, to our great surprise, SGMI-1 completely inhibited lectin pathway activation (28). 
Moreover, SGMI-1 turned to be more potent than SGMI-2 in all assays that started with the PRM-
associated MASPs being in their zymogen form. To this end we conducted many assays. The assays 
differed in serum dilution (we even performed a whole blood assay); we tested MBL- versus 
ficolin-based activation; C3b, C4b deposition or MAC generation. Similarly to SGMI-2, SGMI-1 is 
also pathway selective as it does not inhibit the classical or the alternative pathways or any of the 
C3 and C5-convertases. 
Along the same logic we followed in the case of the SFMI inhibitors, we performed an 
important control experiment, in which we pre-activated the serum either on mannan-coated or 
on acetylated BSA-coated surface to trigger activation of MBL-associated and ficolin-associated 
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MASPs, respectively, and added isolated intact C4 mixed either with SGMI-1 or SGMI-2. In this 
arrangement only SGMI-2 could inhibit C4b deposition, SGMI-1 was totally inert. 
In all, we concluded that in normal human blood MASP-1 is the exclusive activator of 
MASP-2. This means that even though many research groups including ours detected that MASP-2 
can autoactivate in vitro, this capacity of the enzyme simply does not manifest in vivo (28). 
Therefore the previously accepted text book mechanism of lectin pathway activation was 
incorrect. Based on our mono-selective pair of inhibitors we could detect the error and correct it 
(Fig. 2). Soon after, an independent study fully corroborated our findings: Degn et al (29) reported 
the lack of functional lectin pathway in a human patient genetically deficient in MASP-1 (and 
MASP-3) and they also showed that adding exogenous MASP-1 to the serum of the patient 
restored the lectin pathway. 
Our monospecific inhibitors also allowed us to answer a more subtle but nevertheless very 
important and long-lasting question: what are the relative contributions of MASP-1 and MASP-2 to 
generating the cleaved C2 component of the C4b2a C3 convertase? We determined this through 
measuring C3 deposition on C4b-saturated surfaces using SGMI-1 and SGMI-2. When MASP-1 was 
inhibited by SGMI-1, the level of C3 deposition dropped to 43.5% of the non-inhibited experiment. 
When MASP-2 was inhibited by SGMI-2, the level of C3 deposition dropped to 61% of the non-
inhibited value. The two independent measurements unequivocally showed that MASP-1 is the 
major contributor of the C2 cleavage. When applying both inhibitors at the same time the level of 
C3 deposition was reduced to 3.3%. 
The fact that the inherent auto-activating capacity of MASP-2 observed in various in vitro 
assays from several research groups did not manifest in normal human blood inspired us to 
quantitatively determine the auto-activation and cross-activation capabilities of MASP-2 and 
MASP-1 (30). 
 
Zymogen MASP-1 exerts the first proteolytic steps 
 
Auto-activation is a two-step process. It starts with a proenzyme molecule activating 
another proenzyme molecule of the same protease. We introduced the term for this step: 
zymogen autoactivation. The next step is when the already activated proteinase activates a 
zymogen molecule of its own type and we call that autocatalytic activation. Both activation types 
have potential cross-activation versions where the two enzymes are different and we call these as 
zymogen-zymogen cross-activation and active-zymogen cross-activation. 
In the context of two enzymes (in this case MASP-1 and MASP-2) there are two zymogen 
autoactivation reactions, two autocatalytic activation reactions, two zymogen-zymogen cross-
activation reactions and two active-zymogen cross-activation reactions, altogether 8 pair-wise 
enzyme-substrate reactions to analyze. 
In such assays a zymogen molecule is both a (usually low-activity) enzyme as well as a 
substrate. As the reaction proceeds, the concentration of the zymogen gradually decreases while 
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that of the activated form increases. Moreover, as catalytic efficiency of the zymogen and the 
active form are usually several orders of magnitude different, it is a challenge to de-convolute 
individual catalytic constants from such reactions. 
In order to make the system manageable we separated the substrate and enzyme roles of 
the zymogens into two mutant molecules. By producing a zymogen in which the catalytic triad 
serine is replaced with an alanine we generated a form that can act only as a substrate, and even 
when it is processed at the activation site, the cleavage results in an inactive species. In the other 
type of mutants we replaced the activation cleavage site Arg with a Gln rendering this site un-
cleavable by trypsin-like proteinases. Such mutant proenzymes cannot function as substrates but 
can fulfill the enzymatic role of the (low activity) proenzyme. 
We aimed to compare the relative inherent capabilities of the MASP (pro)enzymes to 
perform these auto- and cross-activation reactions and therefore we placed the project out of the 
context of the PRMs using recombinant catalytic fragments of the MASPs. Cleavages were 
followed as a function of time on SDS PAGE, the gels were analyzed by densitometry, and 
individual rates as well as kobs/[E]T (~kcat/KM) values were calculated. The 8 pair-wise results are 
summarized in Fig. 3 (30).  
The study led to the following major conclusions. Proenzyme MASP-2 has a hardly 
measurable zymogen autoactivation capability. Previous experiments detected zymogen MASP-2 
autoactivation only at very high local concentration of the proenzyme either on an ion-exchange 
chromatography column or in the context of MBL, saturated with the proenzyme. As we already 
proved that in vivo only MASP-1 activates proenzyme MASP-2, it follows that this kind of high local 
concentration of proenzyme MASP-2 is not achieved in vivo. Note that proenzyme MASP-2 has a 
low plasma concentration representing only a minor component of the MBL (and ficolin)-
associated proteins (31, 32). 
On the other hand the quantitative study clearly showed that once MASP-2 is activated it 
becomes a potent activator of both proenzyme MASP-2 and pro-enzyme MASP-1. Based on the 
results of our (and others) in vitro studies combined with our X-ray structures of activated and 
zymogen MASP-2 we built a structural model showing that the substrate-binding site of activated 
MASP-2 can readily accommodate the activation site segment of zymogen MASP-2 due to the 
high-level structural plasticity of the MASP-2 zymogen (14). We also argued that the structural 
models are fully compatible with zymogen MASP-2 autoactivation. Nevertheless structural 
modeling has its own limitations and it seems that although such autocatalytic process is not 
structurally hindered, it proceeds at a very low, biologically irrelevant rate. This very low rate 
might be a reflection of an evolutionary past when MASP-2 zymogen autoactivation might have 
been biologically relevant. 
Another important conclusion is that zymogen MASP-1 is a potent activator of both MASP-
1 and MASP-2 proenzymes. This suggests that once the PRM binds to its target molecular pattern 
the very first catalytic step is carried out by zymogen MASP-1, which means that proenzyme 
MASP-1 is the principal conductor of the entire activation process. Once zymogen MASP-1 
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becomes activated it gains an overwhelming capacity to activate both proenzyme MASP-1 and 
MASP-2. 
 
The activation mechanism or PRM-MASP complexes 
 
Although by combining many different types of experiments we could finally construct a 
coherent model of consecutive enzymatic events, we note that it is still largely unknown how 
these steps are orchestrated topologically into the context of the various PRM complexes. Using 
small-angle X-ray scattering and electron microscopy measurements, it was shown recently that in 
the MBL-MASP-1 complex (that contains a dimer of zymogen MASP-1 molecules) the serine 
protease domains of the MASP-1 protomers are protruded from the cone defined by the 
collagenous stalks of MBL (33). It suggests that the catalytic region of MASP-1 is always accessible 
for the substrates even in the fluid phase. This is in sharp contrast to the previous models of the 
zymogen C1 complex where the catalytic domains of the C1r and C1s serine proteases are 
embedded inside the cone (34-36). After ligand binding by C1q, the zymogen activation steps 
occur intramolecularly and, as a result of a significant conformational change, the catalytic 
domains of the C1s molecules emerge at the outer surface of the C1q scaffold. The situation in the 
case of the lectin pathway activation could be quite different. Degn et al. (37) showed that 
clustering of the MBL/ficolin-MASP complexes on a proper activation surface results in the cross-
activation of the zymogen proteases in an intercomplex manner. According to this model the 
conformational changes followed by the ligand binding of PRMs do not play a role in the activation 
process, what is really important is the correct juxtaposition of the activation complexes on the 
surface. Although the evidences supporting for both models are convincing, it seems quite 
intriguing that the classical and the lectin pathways use quite different mechanisms for activation. 
Further investigations are needed to resolve this paradox. 
 
Interactions with other complement pathways 
 
General considerations 
 
Since the alternative pathway serves as an amplification loop for both the classical and the 
lectin pathways, there is an obvious connection between the three activation pathways of 
complement. In this part other possible connection points will be discussed regarding the roles of 
MASPs and MBL in the initiation of the other two pathways. The similarity of the lectin pathway 
complexes with C1 suggests that their components might cross-act during the formation of the 
classical C3 convertase. 
There are also many indications that the lectin pathway plays an important role in initiation 
of the alternative pathway, however the mechanistic details are largely unknown. Nevertheless 
MASP-3 has emerged recently as the activator of pro-FD, which provides an established link 
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between the two pathways and also a well defined function for MASP-3. Other potential but still 
controversial links between the two pathways are also discussed. 
 
Lectin and classical pathway analogies and potential cross-binding 
 
The complement activating capacity of MBL has been originally described through the 
interaction of MBL and the C1r2s2 tetramer of the classical pathway (1, 38). Especially the higher 
oligomeric forms of MBL (the pentameric and hexameric variants) were efficient in activating the 
C1r2s2 tetramer (2). These early experiments showed that the frame of the MBL molecule is 
compatible with the proteases of the classical pathway. A thorough study by Phillip and colleagues 
(35) provided quantitative data on cross-binding interactions between C1q and MASP dimers, and 
also on PRMs of the lectin pathway and the C1r2s2 tetramer. These cross-binding interactions are 
generally quite strong, and they are in the range of typical protein-protein interactions (Kd ~ 30-
100 nM), however the interaction strength of the proteases with the cognate PRMs are at least 
10-fold stronger. The relative affinities suggest that non-cognate complexes might exist in vivo, 
though likely at low proportion compared to cognate complexes. On the other hand in case of 
genetic deficiencies their proportion might be more significant. 
It is also noteworthy that the only natural inhibitor of the classical pathway, C1 inhibitor, is 
also a main inhibitor of both MASP-1 and MASP-2 (39, 40). In this respect the regulation of the two 
pathways are strongly interconnected. 
The C1r2s2 tetramer is formed through the heteromeric interaction between the N-terminal 
CUB1-EGF-CUB2 regions of the two enzymes. In this regard the C1 complex can be viewed as a 
hexameric C1q molecule accommodating two C1r-C1s heterodimers. Analogous interactions were 
described for MASP-1, MASP-2 and MBL as well. MASP-1 and MASP-2 can also form heterodimers, 
at least in vitro (41), and co-complexes of MASP-1, MASP-2 and MBL were detected in human 
serum (42, 43). These co-complexes can either contain one MASP-1-MASP-2 heterodimer, or two 
homodimers of each enzyme. 
In all the architecture of C1 and lectin pathway PRM-MASP complexes is very similar, many 
analogies exist, their regulation is common, and possible in vivo cross-binding of PRMs with non-
cognate proteases cannot be ruled out. 
 
MASP-3 activates pro-FD of the alternative pathway 
 
Factor D (FD) catalyses the proteolytic reaction that leads to the formation of the 
alternative pathway C3 convertase. FD has a very restricted substrate specificity, it cleaves factor B 
(FB) in complex with C3b, but not free FB (44). This role of FD is essential for the initiation of the 
alternative pathway. For a long time factor D has been regarded by most complementologists to 
exist only in the active form in the circulation (45), and it was thought that FD is activated at the 
site of the synthesis possibly intracellularly (46). Although it is true that FD is predominantly 
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present in the active form in normal blood, the previous picture has become questionable when 
Takahashi and colleagues (47) detected only the proenzyme form of FD (pro-FD) in the serum of 
KO mice lacking both MASP-1 and MASP-3, and consequently no alternative pathway activity was 
observed. Their original explanation was that pro-FD is activated by MASP-1, because recombinant 
MASP-1 (rMASP-1) was capable of doing so in vitro using purified proteins. However, adding 
rMASP-1 to the KO serum did not result in pro-FD activation (47). Later it was proposed that, in 
addition to MASP-1, MASP-3 can also activate pro-FD, and even the proenzyme form of MASP-3 
was suggested to be able to convert pro-FD to FD (48). Meanwhile, others have detected a 
functional alternative pathway in the serum of a 3MC (49) patient lacking both MASP-1 and MASP-
3 concluding that neither enzyme is required for alternative pathway function (29). 
In order to resolve this obvious discrepancy we have decided to use a different approach. 
We aimed to follow the conversion of pro-FD to FD directly in various types of blood samples (i.e. 
plasma and serum) in the presence or absence of specific inhibitors against candidate activators. 
At first we determined the cleavage rates of pro-FD by all three MASPs testing both the 
activated and proenzyme forms, and by thrombin. All active MASPs and thrombin were found to 
be efficient pro-FD activators in vitro, on the other hand the proenzymes had no significant activity 
(50). These results imply that pro-FD can probably be activated by various active proteases with P1 
Arg specificity in vitro, and the real question is which one of these enzymes (or another enzyme) is 
in the active form when pro-FD activation takes place. In order to follow pro-FD activation in 
complex samples such as serum or plasma pro-FD was labeled with Cy3 fluorescent dye. Because 
the difference in the mobility of FD and pro-FD on SDS-PAGE is very small Cy3-pro-FD was purified 
to ensure that only single labeled pro-FD was used in these experiments. When Cy3-pro-FD was 
added to citrated normal human plasma it was converted to Cy3-FD showing that proteolytic 
activity capable of activating pro-FD was present in this sample (50). Since in citrated plasma 
neither the complement system nor the coagulation system is expected to be activated we 
concluded that a pro-FD activator is present in normal human blood under “resting” conditions. 
This is consistent with the previous observation that in normal blood the predominant form of FD 
is the active enzyme (45). 
When our previously developed MASP-1 specific inhibitor, SGMI-1, and the MASP-2 specific 
inhibitor, SGMI-2, was added at concentrations (100 nM) capable of completely inhibiting the 
corresponding enzymes, pro-FD activation was not significantly altered in plasma, suggesting that 
neither of these enzymes is a direct pro-FD activator. Surprisingly, at high micromolar SGMI-2 
concentration pro-FD activation was slowed-down significantly. Incidentally SGMI-2 happens to be 
a very poor MASP-3 inhibitor (Ki~5µM) (28), hence the effect was consistent with MASP-3 being 
the candidate for pro-FD activation. This suspicion was confirmed when the active recombinant 
catalytic fragments of MASP-1, MASP-2, and MASP-3 were added separately to plasma along with 
labeled pro-FD, and only MASP-3 accelerated the conversion of pro-FD to FD (50). These results 
strongly implicated a role of MASP-3 in pro-FD activation, however the involvement of other 
proteases could not be ruled out. 
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Therefore we recently developed an inhibitor specific for activated MASP-3. Our latest 
results using this MASP-3 specific inhibitor (Dobó, Szakács, Oroszlán, Kortvely, Kiss, Boros, Szász, 
Závodszky, Gál, and Pál unpublished results) have unambiguously proven that active MASP-3 is the 
exclusive and direct activator of pro-FD in resting human blood (Fig. 4). This novel inhibitor 
completely blocked the activation of labeled pro-FD in citrated plasma, EDTA plasma, and even in 
hirudin plasma. Low level activation was still detectable in serum in the presence of the MASP-3 
specific inhibitor suggesting that other enzymes (e.g. thrombin) can serve as pro-FD activators, but 
only during ongoing coagulation. This observation can explain why alternative pathway activity can 
be seen in MASP-3 deficient serum in certain cases (29, 51). In MASP-3 sufficient blood, however, 
there is no need for other enzymes, since active MASP-3 activates pro-FD efficiently in the absence 
of the activation of coagulation cascade. Our results also imply that a significant portion of MASP-3 
has to be in the active form even in resting blood. 
 
Potential roles of MASPs and MBL in alternative pathway activation 
 
In the following part other implicated roles of MASPs and MBL in the activation of the 
alternative pathway are discussed, however, these roles are either debated or the mechanism is 
not yet established and require further studies to prove their in vivo relevance. MASP-1 was 
shown early after its discovery to directly cleave C3 (52), however the cleavage rate was rather 
low (7). MASP-1 actually exhibited a 30-fold higher activity toward C3(NH3), the inactivated form 
of C3 resembling C3(H2O) than toward intact C3 (7). In this respect it is questionable whether 
MASP-1 is capable of directly activate the alternative pathway causing C3b deposition. MASP-2 
was shown to exhibit similar activity toward C3, however, considering the 20-fold lower 
concentration of MASP-2 compared to MASP-1, this activity seems to be even less relevant (7). 
MASP-2 was shown to be involved in the pathomechanism of renal ischemia reperfusion 
injury in a mouse model. MASP-2 deficiency reduced C3 deposition in a C4 independent fashion 
compared to wild-type mice (53). This indicates that MASP-2 might be involved somehow in the 
activation of the alternative pathway, and the mechanism is different from the established lectin 
pathway activation route. Similarly, MBL dependent activation of the alternative pathway was 
published. This activation was independent of C2, C4 (54), moreover it was shown to be 
independent of MASP-2. The mechanistic details of this activation are largely unknown, though 
MASP-1 may possibly be involved in the process. 
The active form of MASP-3, as described above, activates pro-FD. In addition to its pro-FD 
cleaving activity MASP-3 was also implicated in direct FB activation (48). One might wonder 
though which protease(s) activate(s) MASP-3, especially in resting blood. MASP-1 has been shown 
to be able to activate MASP-3 (30) in vitro, and the possibility that MASP-2 has similar activity is 
also viable. In this regard MASP-1 can contribute, although indirectly, to the alternative pathway 
as postulated by Takahashi et al (47). 
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Taken together the lectin pathway of complement is probably intricately intertwined with 
the alternative pathway, but our knowledge about the mechanistic details, with the exception of 
pro-FD activation by MASP-3, is very limited. 
 
 
Interaction between the different cascade systems in the blood 
 
Common origin of proteolytic cascades 
 
The complement and the coagulation systems are closely related in terms of evolution and 
function. The horseshoe crab, which is regarded as a “living fossil” of 500 million-years, has a 
single proteolytic cascade system that fulfills both the roles of coagulation and immune defense at 
the same time (55). Later in evolution, seemingly distinct cascade systems diverged from the 
ancient one with more specialized functions. Although, for practical and didactical reasons we 
distinguish between complement, coagulation and other cascades in vertebrates, we must keep in 
mind that these systems communicate with each other in many ways. In many pathophysiological 
situations (e.g. in case of injury) both the complement and the coagulation systems are activated 
at the same time, and the two systems augment each-other’s efficacy through cross activation 
(56). This could be a beneficial phenomenon when restoring the homeostasis of the body. On the 
other hand, the synergistic effect of the proteolytic cascades can result in the development of 
uncontrolled inflammatory conditions that could be detrimental if not treated. In the case of the 
cardiovascular diseases the simultaneous activation of the complement and the coagulation 
systems may contribute to the development and worsening of atherosclerosis and 
atherothrombosis (57). The cross talk between the blood-borne proteolytic cascades is a subject of 
several reviews (58, 59). In this chapter we concentrate only on the role of the lectin pathway, 
especially that of MASPs, in the coagulation and in the bradykinin generation. 
 
The role of MASP-1 and MASP-2 in coagulation 
 
MASP-1 can be viewed as an atypical complement protease, since it has much more 
relaxed substrate specificity compared to other members of the C1r/C1s/MASPs family of serine 
proteases. While C1r, C1s and MASP-2 have only a few substrates typically among the components 
of the complement system, MASP-1 has many substrates including non-complement proteins. The 
first non-complement substrates identified for MASP-1 were fibrinogen and Factor XIII (plasma 
transglutaminase) (60-62). Analysis of the proteolytic activity of MASP-1 by using synthetic 
oligopeptide substrate libraries demonstrated that MASP-1 is a thrombin-like enzyme: at the P1 
site it shows extreme Arg selectivity and it cleaves typical thrombin substrates such as VPR-AMC at 
high rate (7, 63). Using purified proteins, MASP-1 cleaves fibrinogen and liberates fibrinopeptide B, 
a chemotactic factor for neutrophils (61). Unlike thrombin, however, it does not generate 
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fibrinopeptide A which indicates that MASP-1 cleaves the α-chain of fibrinogen differently. It was 
shown that MASP-1 cleaves and activates Factor XIII similarly to thrombin although with lower 
efficiency. An interesting observation is that MASP-1 cleaves the Val34 (P4 residue) polymorphic 
variant of Factor XIII faster than the Leu 34 variant, while thrombin shows the opposite preference 
(64). Since the Leu34 variant shows protective effect in cardiovascular diseases it is speculated 
that the MASP-1 mediated cleavage of the Val34 variant might be disadvantageous and may 
contribute to the higher incidence of thrombotic events associated with the Val34 variant. MASP-1 
also directly activates thrombin-activatable fibrinolysis inhibitor (TAFI) (64). TAFI is a 
carboxypeptidase (carboxypeptidase B2) which prevents fibrinolysis by removing C-terminal 
lysines from partially digested fibrin clot thereby preventing binding of tissue type plasminogen 
activator. Intriguingly it also inactivates anaphylatoxins (C3a, C5a) more efficiently than plasma 
carboxypeptidase N (65, 66).  
The role of MASP-1 in coagulation was further studied in plasma and in whole blood (67). 
Addition of MASP-1 to plasma or whole blood induced and promoted clot formation by a 
thrombin-dependent manner. It was also demonstrated that MASP-1 cleaves and activates 
prothrombin. Although the cleavage sites preferred by MASP-1 (R155, R271, R393) do not exactly 
match that of Factor Xa (R320, R393) and thrombin (autolytic cleavage at R155 and R284), MASP-1 
generate thrombin species that are active in coagulation (68). These results indicate that the clot 
formation ability of MASP-1 in a physiological setting is a consequence of its proteolytic action on 
prothrombin rather than the direct cleavage of fibrinogen. An interesting observation is that 
MASP-1 has a clear influence on the final structure of the clot. The proteolytic activity of MASP-1 
in the plasma resulted in the formation of clot having a less dense structure but with thicker fibrin 
fibers (64). A less dense structure usually means shorter lysis time. Surprisingly this clot is more 
resistant to fibrinolysis than the clot formed without addition of MASP-1. A possible explanation 
could be that MASP-1 activity promotes incorporation of complement components (e.g. C3b) into 
the fibrin mesh. The TAFI activating ability of MASP-1 can also diminish the efficacy of the 
fibrinolysis. 
Another study showed that MASP-2 is also capable of activating prothrombin, moreover in 
an in vitro experiment, binding of MBL-MASP-2 complexes to bacterial surface (S. aureus) elicited 
fibrin deposition when incubated with purified prothrombin and fibrinogen (69). The thrombin 
generating potential of MASP-2 is quite low (about 4-5% the rate observed with purified Factor Xa) 
and this value would be even lower in a pathophysiological situation where Factor Xa is present in 
the prothrombinase complex together with Factor Va on negatively charged phospholipid 
membranes. It is hard to estimate the contribution of MASP-2 to the prothrombin activation in a 
pathophysiological situation, but given that the concentration of MASP-2 in the plasma is much 
lower than that of MASP-1 and the activation of MASP-2 is MASP-1 dependent, we can conclude 
that the procoagulant activity of the lectin pathway is driven mainly by MASP-1. This assumption is 
supported by two in vivo observations: 1.) MASP-1 knock-out mice show prolonged bleeding time 
upon tail tip excision (70), and 2.) MASP-1 knock-out mice have significantly decreased ferric 
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chloride-induced occlusive arterial thrombogenesis (71). Moreover, MAp44 (alias MAP-1), a 
natural truncated N-terminal fragment of MASP-1 which is capable of displacing MASPs in the 
MBL-MASPs complexes also showed protective effects in the ferric chloride coagulation (thrombus 
formation) model (72). 
The procoagulant activity of the lectin pathway may reflect an ancient form of innate 
immune defense, which is not widely explored in mammals. Limited, localized coagulation, fibrin 
polymer formation may limit the spread of invading microorganisms within the body (73). Fibrin 
deposited on the surface of the pathogens may immobilize them, cause their aggregation, or at 
least serve as adhesion points for phagocytes that are recruited by the released fibrinopeptides. 
 
Common regulators 
 
In the light of the above facts it is not surprising that the regulation of the two cascade 
systems is also closely connected. The major inhibitors for the complement and coagulation 
proteases are serpins in the blood. C1 inhibitor is regarded as the major inhibitor of the classical 
and the lectin pathways, since it inactivates C1r, C1s, MASP-1 and MASP-2 by trapping them into a 
covalent enzyme-inhibitor complex (74). C1 inhibitor also has anti-coagulant effect by inhibiting 
Factor XIa and Factor XIIa. We have shown recently, that antithrombin, a serpin responsible for 
the regulation of thrombin, is a very effective lectin pathway inhibitor (40). In fact, in the presence 
of heparin antithrombin is a better inhibitor of MASP-1 than C1 inhibitor (22). Very recently two 
independent publications corroborated the role of antithrombin in lectin pathway regulation 
detecting MASP-1-antithrombin complexes in the blood of patients having various diseases (e.g. 
HAE, SLE, polytrauma) (75, 76). The latter publication also demonstrates that blood clotting 
activates the lectin pathway (76). Both activated platelets and fibrin clots triggered the activation 
of MASP-1 and MASP-2. If this is the case, then the two systems, the coagulation and the lectin 
pathways, activate each-other reciprocally mounting a powerful response by means of a positive 
amplification circle. If we want to prevent harmful activation of the cascade systems (e.g. in the 
case of thrombosis) we should target both pathways simultaneously, just like the natural, 
endogenous inhibitors (C1 inhibitor, antithrombin) do. 
 
MASP-1 and the kinin generating system 
 
Bradykinin is an important inflammatory mediator peptide: it causes vasodilatation, 
increases vascular permeability and elicits production of second-generation mediators (77). It is 
generated from high-molecular-weight kininogen as a result of the activation of the kallikrein-kinin 
cascade (78). Uncontrolled release of bradykinin during hereditary angioedema (HAE) leads to 
recurrent tissue swelling attacks. HAE is characterized by functional C1 inhibitor deficiency. 
Besides the complement and the coagulation systems C1 inhibitor also regulates the kallikrein-
kinin cascade. Plasma kallikrein, the executive enzyme of the cascade, that is responsible for 
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bradykinin generation, is also inhibited by C1 inhibitor. Using a proteomic approach we discovered 
that high-molecular-weight kininogen is a potential natural substrate of MASP-1 (79). 
Recombinant MASP-1 and purified natural MBL-MASPs complexes were able to cleave high-
molecular-weight kininogen and liberate bradykinin. Although the efficiency of this process is low 
compared to the efficiency of the plasma kallikrein mediated cleavage, it could be important for 
two reasons. First, during infection, when the lectin pathway activates locally, the bradykinin 
production could contribute to local inflammation of the tissues, which is a part of the innate 
immune response. Second, since C1 inhibitor is a natural inhibitor of plasma kallikrein and MASP-
1, the reduced functional C1 inhibitor concentration in the HAE patients results in the increased 
activation of MASP-1 yielding an excess bradykinin production. Taken into account the high 
autoactivation potential of MASP-1, it is also possible that MASP-1 contributes to the elevated 
baseline level of bradykinin observed in the blood of the HAE patients (80). Indeed, a recent 
publication reported that that there is a significant amount of circulating MASP-1-C1 inhibitor 
complex in the resting blood of healthy individuals (75). This means that MASP-1 is being 
continuously (auto)activated in the plasma at a slow rate (similarly to the “tick over” of C3), but 
the active MASP-1 is present only for a limited period of time, since it is inactivated by C1 inhibitor 
(and possibly by antithrombin). In the meantime, however, active MASP-1 can digest kininogen 
and probably other potential physiologically important substrates. In the HAE patients the 
uncontrolled activation of MASP-1 can lead to excess bradykinin generation that could contribute 
to the initiation and/or the maintenance of the edematous attacks. 
 
The promiscuity of MASP-1 
 
As we have seen, MASP-1 can interact with numerous substrates and inhibitors. This is 
quite atypical among the complement serine proteases which usually have very restricted 
substrate specificity. The crystal structure of MASP-1 explains the unique features of this serine 
protease (22). The substrate binding cleft of MASP-1 is relatively large and open capable of 
accommodating different substrate molecules, while the same region of C1r, C1s and MASP-2 is 
restricted by bulky side chains. The catalytic domain of MASP-1 resembles that of trypsin rather 
than other complement proteases. Nevertheless, there are two structural features that restrict the 
activity and specificity of MASP-1. Similarly to Factor D, the crucial Asp residue on the bottom of 
the substrate binding pocket is engaged with an Arg side chain through a salt bridge. The unusually 
long Loop B (60-loop), as in the case of thrombin, may constrict the substrate specificity.  
Taken together, MASP-1 is an atypical complement protease, which can cleave and activate 
many proteins of the coagulation system maintaining and ancient link between blood clotting and 
innate immune response (Fig. 5). 
 
The role of MASPs in cell activation 
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Interaction between humoral and cellular immunity 
 
Similarly to the extensive interaction of plasma cascade systems described above, subsets 
of immune system are also intertwined and synergistic. To understand the function of such sub-
systems (e.g. T cell response, complement system, NK cells) didactic separation was needed and 
amenable, however, when the immune response occurs in vivo, none of these systems works 
alone. We have recognized the interaction between innate- and adaptive immunity (e.g. the 
activation of complement classical pathway), and the synergism of humoral and cellular immunity 
(e.g. the antibody dependent cell-mediated cytotoxicity) long ago. Initially, complement system 
was considered as a cascade of soluble proteins, which has a single ultimate goal: to lyse the 
invading microbial cells. In vitro and in vivo experiments, as well as the exploration of deficiencies 
of different complement factors, have taught us that complement system is a fine-tuned regulator 
of immunity, it can be activated via several distinct molecular patterns and specific receptors (i.e. 
antibodies), and it differentially responds to these stimuli by opsonization, chemotaxis initiation, 
cell activation and lysis. Why is it important to have multiple routes of crosstalk between 
complement system and cellular immunity? To overwhelm invading microbes or clear away the 
cellular debris of damaged tissues, kinetics is substantially important. The earlier the immune 
response is turned on the higher chance of the body has to win this battle. Moreover, pathogens 
evolved a wide variety of escape mechanisms to avoid the immune system. Crosstalk between the 
parts of immune system decreases the effectiveness of such microbial tricks. 
 
MASP-1 activates endothelial cells through PAR cleavage 
 
MASP-1 is associated with lectin pathway pattern recognition receptors (MBL, CL-K1, CL-L1 
and ficolins) and is readily autoactivated upon the pathogen/danger associated molecular patterns 
are recognized by the lectin pathway receptors. This occurs within minutes and is under the 
control of only a few serine protease inhibitors, mainly C1 inhibitor and antithrombin. We showed 
that MASP-1 (similarly to thrombin) can cleave protease activated receptors (PARs) on the surface 
of endothelial cells, which results in the pro-inflammatory activation of endothelial cells (81). 
Activation of p38 MAPK, pCREB, NFκB and JNK pathways along with Ca-mobilization led to 
cytokine production and altered adhesion molecule pattern in a HUVEC model (82, 83 ). Elevated 
IL-8 secretion and E-selectin expression resulted in increased neutrophil chemotaxis and adhesion 
forces toward endothelial cells. The endothelial cell stimulating capability of MASP-1 is attributed 
only to fully active MASP-1 molecules. Neither zymogen form nor serine-to-alanine mutated 
inactive form of MASP-1 was able to activate HUVECs (84 ). These findings support our hypothesis 
that microbial infection or tissue damage is necessary to trigger MASP-1 induced, endothelial cell 
driven neutrophil activation (Fig. 6). The direct effect of MASP-1 on neutrophil granulocytes or 
other subsets of leukocytes has not been studied yet. It has long been known that anaphylatoxins 
(C3a, C5a) possess similar neutrophil chemotactic and activating effects as the products of MASP-1 
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induced endothelial cells. Therefore, the question emerges: why do we need such overlapping 
functions of two subsequent factors of the complement system? The neutrophil attracting and 
activating effects of MASP-1 are triggered solely by the lectin pathway activity, and are regulated 
by C1 inhibitor and at endothelial cell level but not by other complement regulatory proteins. In 
contrast, C3a and C5a, as central products of all three complement pathways, are controlled by 
several complement regulators (e.g. C4BP, factor H, DAF, MCP, factor I) but not by endothelial 
gene expression. Therefore, the synergism of complement system and cellular immunity 
(especially neutrophil granulocytes in this context) by MASP-1 and anaphylatoxins completes each 
other’s function providing fine-tuned immune regulation (Fig. 6). Liver is the predominant organ 
for the synthesis of plasma proteins, including most of the complement factors and other proteins 
participating in the acute phase response. Hepatic stellate cells, the hepatic equivalent of 
pericytes, can also be activated by MASP-1 (85 ), which results in a fibrinogenic myofibroblast 
phenotype. This reaction also requires the active form of MASP-1: zymogen form is similarly 
inactive as in the endothelial cell model. Although the physiological role of quiescent hepatic 
stellate cells are largely unknown, they may interact with other hepatic cell types, such as 
hepatocytes, liver sinusoidal endothelial cells and Kupffer cells (86 ), and may be involved in 
tolerogenic antigen presentation of the liver (87 ). 
 
Possible role of MASP-2 and MASP-3 in cell activation 
 
We know much less about the role of MASP-2 beyond lectin pathway activation. In contrast 
to MASP-1, MASP-2 has a stringent substrate binding specificity. In fact, it has no other known 
substrates than C2, C4 and possibly prothrombin, therefore it was not unexpected that we could 
not detect any effects of MASP-2 on HUVECs (81 ). However, Asgari et al. found that MASP-2 has a 
critical role in the renal ischemia/reperfusion injury even in the absence of C4 (53). It suggests the 
presence of other substrate(s) of MASP-2 than C4 and C2, since C4 is necessary to the complement 
activation through the lectin pathway, whereas C2 cleavage can also be accomplished by MASP-1. 
In this model, MASP-2 deposition could be detected on the peritubular surface, which raises the 
question whether MASP-2 is able to interact with cells directly. Moreover, van der Pol et al. also 
described similar detrimental role of MBL in renal ischemia/reperfusion injury (88 ). Although they 
found that C3 or downstream complement activation is not responsible for the action of MBL, the 
possible role of MASP-2 (and the other MASPs) was not excluded. If MASP-2 has indeed a direct 
effect on various cell types, the question is still open, which receptor(s) it can use, since MASP-2 
has no PAR cleaving activity. 
The substrate specificity, the possible natural inhibitors and the exact physiological role of 
MASP-3 is still largely unknown. Besides its factor D activating ability, published recently (50), 
MASP-3 is involved in several processes in ontogenesis, demonstrated by the bone-, neuronal- and 
sexual- malformations associated with its mutation in 3MC syndrome (49, 89, 90). Although MASP-
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3 may cleave soluble hormone-like proteins to exert its action (91), we could not exclude the 
direct cell activating effects of MASP-3 either. 
Apart from their enzymatic activity, all MASPs can influence the interaction of MBL or L-
ficolin with CR1, since their binding site to the collagen stalks of lectin pathway receptors are 
overlapping (92). However, it is still not known, whether this in vitro competition is relevant in 
vivo, and what the possible consequences of the reaction are. 
In summary, MASPs (and especially MASP-1) are not only the keystone enzymes of the 
complement lectin pathway and a participant of other plasma cascade systems, but they can 
activate different cell types implicating an intimate crosstalk between humoral immune system 
and other cellular systems of the body through MASPs, which leads to a more effective and more 
complex immune response. 
 
Conclusion and perspectives 
 
As we have seen, the MASPs play multiples roles in the initiation of the innate immune 
response. MASP-1 and MASP-2 are the indispensable enzymes responsible for lectin pathway 
activation, while the proteolytic activity of MASP-3 represents a key linkage between the lectin 
and the alternative pathway. MASPs also contribute to physiological processes outside the 
complement activation. MASP-1 and MASP-2 may be involved in other proteolytic cascades, such 
as the coagulation and the kinin generation pathways. MASP-1 has also been shown to directly 
activate different cells connecting the humoral and cellular immunity. These findings demonstrate 
that the complement system is a part of a lager proteolytic network and MASPs have multiple 
interaction partners (substrates, inhibitors, PRMs) in this network. In this respect exciting 
discoveries are expected in the future. The role of MASP-3 in the embryonic development is also 
an intriguing question. Although MASP-3 seems to be a protease with restricted substrate 
specificity and low activity, its deficiency leads to the development of 3MC syndrome. The only 
established known MASP-3 substrate is FD, however FD deficiency does not cause 3MC syndrome 
(but that of CL-K1 does). We can conclude that MASP-3 (especially CL-K1-MASP-3 complex) has at 
least one unidentified substrate that is important in the ontogenesis. The uncontrolled activity of 
MASPs may also contribute to the development of various disease conditions. HAE, ischemia-
reperfusion injury, atypical haemolytic uraemic syndrome, age-related macular degeneration, 
rheumatoid arthritis are only a few examples of diseases where inhibition of the proteolytic 
activity of MASPs may have therapeutic benefit. Development of MASP inhibitors (small 
molecules, recombinant proteins, inhibitory antibodies) are underway and may be tested soon in 
the clinical practice (93). 
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Figure legends 
 
Fig. 1. Domain structure of MASPs and related proteins. MASP-1, MASP-3 and MAp44 are the 
products of the MASP1 gene. MASP-1 and MASP-3 differ only in the SP domain, while MAp44 is a 
shortened protein with 17 unique C-terminal amino acids following the CCP1 domain. MASP-2 and 
MAp19 are the products of the MASP2 gene. MAp19 is a shortened protein with 4 unique amino 
acids at the C-terminus following the EGF domain. Shared domains with the same sequence are 
depicted with identical colors. 
 
 
Fig. 2. Mechanism of the major arm of the complement lectin pathway. When PRM-MASP 
complexes bind to activator surfaces MASP-1 autoactivates first, then it activates MASP-2. MASP-2 
cleaves C4 and both enzymes can activate C2, resulting in the formation of the classical C3 
convertase C4bC2a. Red arrows represent proteolytic cleavage pointing from the enzyme to the 
substrate. Gray arrows designate conversion, while gray curved lines indicate a non-enzymatic 
signal. 
 
 
Fig. 3. Zymogen MASP-1 is the initiator of lectin pathway activation. Zymogen and active MASP-1 
and MASP-2 activities were measured on themselves (autoactivation) and on each-other (cross-
activation) using recombinant catalytic fragments. Non-activatable mutant variants served as 
models for the zymogen state, while the wild-type enzymes were used to measure the activities of 
active state. The active-site Ser to Ala mutants, which are completely inactive, were used as 
substrates. The kobs/[E]T values were calculated, which are as good estimates for the catalytic 
efficiencies (kcat/KM). Please note the logarithmic scale on the y axis! MASP-1 is the main driver 
during the entire process, however, in the initial zymogen phase only MASP-1 has significant 
activity, hence the whole activation process is dependent on the inherent activity of zymogen 
MASP-1. 
 
 
Fig. 4. Fundamental link between the lectin and the alternative complement pathways. MASP-3, 
component of the lectin pathway, was found to be the major activator of pro-FD in general, and 
the exclusive activator of pro-FD in resting human blood. Only active MASP-3 can activate pro-FD. 
Since FD is an essential initiator of the alternative pathway, the presence of active MASP-3 is 
required for the normal functioning of the alternative pathway. Red arrows represent proteolytic 
cleavage pointing from the enzyme to the substrate, while gray arrows indicate conversion. 
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Fig. 5. The promiscuity of MASP-1. In addition to its complement activating capacity, MASP-1 was 
also shown to be able to boost coagulation, and contribute to a more powerful inflammatory 
reaction through activation of endothelial cells and bradykinin release. The inhibitors of MASP-1 
are shared between the complement system and coagulation. 
 
 
Fig. 6. The lectin pathway crosstalk hypothesis. Microbial (especially bacterial and fungal) 
infections and damaged self structures provide danger signals (PAMPs and DAMPs, respectively) 
to the immune system. They are perceived by pattern recognition molecules, such as complement 
lectin pathway receptors: MBL, ficolins and collectins. Upon this recognition, MASP-1 
autoactivates. At this point the response branches, active MASP-1 can cleave MASP-2, which carry 
on the complement activation providing chemotactic factors (anaphylatoxins) opsonins and 
membrane attack complexes to hamper the impaired homeostatic conditions. Simultaneously, 
MASP-1 activates endothelial cells to produce pro-inflammatory cytokines and adhesion 
molecules, which together facilitate neutrophil granulocyte chemotaxis to the injured tissues and 
adhesion to the endothelium. Neutrophils, as being the most prominent cell type of the immune 
system against bacteria and fungi, activated by the MASP-1-induced endothelial cells, can be 
further activated by anaphylatoxins and utilize opsonins to clear microbes and cellular debris with 
high efficiency. This novel cooperation between neutrophils and complement lectin pathway is 
orchestrated by MASP-1. 
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